Castleview Partners, LLC: MBSX position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Castleview Partners, LLC on MBSX, newest first. How the timeline and the estimate are built.
Castleview Partners, LLC held 337,738 MBSX shares at 2026-09-30 per its 13F-HR filed 2026-10-09.
the latest 13F is the newest step
- period ended2026-09-3013F 337,738 sharesChange vs previous 13F +7,554 shares
3.78% of the 13F portfolio, value $8,625,159.
13F-HR 0001737088-26-000009 filed by Castleview Partners, LLC
Accepted , ingested - period ended2026-06-3013F 330,184 sharesChange vs previous 13F +30,467 shares
3.96% of the 13F portfolio, value $9,015,676.
13F-HR 0001737088-26-000007 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 299,717 sharesChange vs previous 13F +7,911 shares
4.33% of the 13F portfolio, value $8,443,028.
13F-HR 0001737088-26-000004 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 291,806 sharesChange vs previous 13F +17,688 shares
3.82% of the 13F portfolio, value $7,703,678.
13F-HR 0001737088-26-000003 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F 274,118 sharesChange vs previous 13F +45,579 shares
4.1% of the 13F portfolio, value $7,549,210.
13F-HR 0001737088-25-000008 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 228,539 sharesChange vs previous 13F not available
3.76% of the 13F portfolio, value $5,857,843.
13F-HR 0001737088-25-000006 filed by Castleview Partners, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).